|
and Register
Home
Contact Us

AI Agent [AI01]Drug DDT NER

[AI01]Drug DDT NERPublicV1
To extract the names of Drug, Disease and Target (DDT) from Chinese and English patents, literature and news data

Basic Information

Resource URL: /ai/ner/ddt-ner

Request Mode: post

Return Format: application/json

The API can only be called after logging in, click to log in

API Description Document Download

Request Parameters

body
DDTNerRequest
ParameterTypeRequiredDescriptionSample
sourcestringfalse
text source:patent/literature/news, default patent
patent
textstringtrue
The text of drug DDT information needs to be extracted. Chinese text is required to be no more than 500 characters or English text no more than 500 words
Regression of Established Atherosclerotic Plaques, and Treating Sudden-Onset Asthma Attacks, using PARP Inhibitors\n\n\nA method is disclosed for treating and inducing the regression of established atherosclerotic plaques. A method is disclosed for treating asthma, including treatment of an ongoing asthma attack. In both cases, treatment with PARP inhibitors, such as the PARP inhibitor TIQ-A (Thieno[2,3-c]isoquinolin-5-one), can lead to regression of existing disease and symptoms.\n\n\n1. A method for relieving symptoms of a sudden-onset asthma attack in a human; said method comprising administering an effective amount of a PARP inhibitor to a human who is experiencing an acute asthma attack, wherein said PARP inhibitor is administered from 0 hours to 12 hours after the beginning of the sudden-onset asthma attack.\n2. The method of claim 1, wherein the PARP inhibitor is administered from 0 hours to 6 hours after the beginning of the sudden-onset asthma attack.\n3. The method of claim 1, wherein the PARP inhibitor is administered from 0 hours to 1 hours after the beginning of the sudden-onset asthma attack.\n4. The method of claim 1, wherein the PARP inhibitor is selected from the group consisting of TIQ-A; AIQ; 3-AB; PJ-34; 1,5-Isoquinolinediol; 3-Methyl-5-AIQ hydrochloride; 4-Amino-1,8-naphthalimide; 4-Hydroxyquinazoline; 5-AIQ hydrochloride; 5-Iodo-6-amino-1,2-benzopyrone; 6(5H)-Phenanthridinone; EB-47 dihydrochloride dihydrate; NU1025; DR2313; BSI 401; BSI 201; AZD 2281; INO 1001; GPI 15427; GPI 16539; GPI 6150; DR2313; AG14361; NU1025; CEP 6800; AG 014699; ABT-888; minocycline; tetracycline; and derivatives of these compounds.\n5. The method of claim 1, wherein the PARP inhibitor is TIQ-A.\n6. The method of claim 1, wherein the PARP inhibitor is a PARP-1 inhibitor.\n7. A method for inducing the regression of one or more existing atherosclerotic plaques in a human; said method comprising administering an effective amount of a PARP inhibitor over time to a human who has previously been diagnosed with one or more atherosclerotic plaques; then assaying one or more of the plaques to confirm whether one or more of the existing plaques has regressed in response to the PARP inhibitor; and then, if said assaying step indicates that one or more of the plaques has regressed, continuing further administration of the PARP inhibitor for an additional time to induce further regression of one or more of the plaques.\n8. The method of claim 7, wherein the PARP inhibitor is selected from the group consisting of TIQ-A; AIQ; 3-AB; PJ-34; 1,5-Isoquinolinediol; 3-Methyl-5-AIQ hydrochloride; 4-Amino-1,8-naphthalimide; 4-Hydroxyquinazoline; 5-AIQ hydrochloride; 5-Iodo-6-amino-1,2-benzopyrone; 6(5H)-Phenanthridinone; EB-47 dihydrochloride dihydrate; NU1025; DR2313; BSI 401; BSI 201; AZD 2281; INO 1001; GPI 15427; GPI 16539; GPI 6150; DR2313; AG14361; NU1025; CEP 6800; AG 014699; ABT-888; minocycline; tetracycline; and derivatives of these compounds.\n9. The method of claim 7, wherein the PARP inhibitor is TIQ-A.\n10. The method of claim 7, wherein the PARP inhibitor is a PARP-1 inhibitor
langstringtrue
text language, support cn and en
en

Request Sample

  • Curl
  • NodeJs
  • Python
  • Java
curl -X POST "https://connect.patsnap.com/ai/ner/ddt-ner?apikey="
-H "Content-Type:application/json"
-H "authorization:Bearer {token}"
-d '{"lang":"en","text":"Regression of Established Atherosclerotic Plaques, and Treating Sudden-Onset Asthma Attacks, using PARP Inhibitors\\n\\n\\nA method is disclosed for treating and inducing the regression of established atherosclerotic plaques. A method is disclosed for treating asthma, including treatment of an ongoing asthma attack. In both cases, treatment with PARP inhibitors, such as the PARP inhibitor TIQ-A (Thieno[2,3-c]isoquinolin-5-one), can lead to regression of existing disease and symptoms.\\n\\n\\n1. A method for relieving symptoms of a sudden-onset asthma attack in a human; said method comprising administering an effective amount of a PARP inhibitor to a human who is experiencing an acute asthma attack, wherein said PARP inhibitor is administered from 0 hours to 12 hours after the beginning of the sudden-onset asthma attack.\\n2. The method of claim 1, wherein the PARP inhibitor is administered from 0 hours to 6 hours after the beginning of the sudden-onset asthma attack.\\n3. The method of claim 1, wherein the PARP inhibitor is administered from 0 hours to 1 hours after the beginning of the sudden-onset asthma attack.\\n4. The method of claim 1, wherein the PARP inhibitor is selected from the group consisting of TIQ-A; AIQ; 3-AB; PJ-34; 1,5-Isoquinolinediol; 3-Methyl-5-AIQ hydrochloride; 4-Amino-1,8-naphthalimide; 4-Hydroxyquinazoline; 5-AIQ hydrochloride; 5-Iodo-6-amino-1,2-benzopyrone; 6(5H)-Phenanthridinone; EB-47 dihydrochloride dihydrate; NU1025; DR2313; BSI 401; BSI 201; AZD 2281; INO 1001; GPI 15427; GPI 16539; GPI 6150; DR2313; AG14361; NU1025; CEP 6800; AG 014699; ABT-888; minocycline; tetracycline; and derivatives of these compounds.\\n5. The method of claim 1, wherein the PARP inhibitor is TIQ-A.\\n6. The method of claim 1, wherein the PARP inhibitor is a PARP-1 inhibitor.\\n7. A method for inducing the regression of one or more existing atherosclerotic plaques in a human; said method comprising administering an effective amount of a PARP inhibitor over time to a human who has previously been diagnosed with one or more atherosclerotic plaques; then assaying one or more of the plaques to confirm whether one or more of the existing plaques has regressed in response to the PARP inhibitor; and then, if said assaying step indicates that one or more of the plaques has regressed, continuing further administration of the PARP inhibitor for an additional time to induce further regression of one or more of the plaques.\\n8. The method of claim 7, wherein the PARP inhibitor is selected from the group consisting of TIQ-A; AIQ; 3-AB; PJ-34; 1,5-Isoquinolinediol; 3-Methyl-5-AIQ hydrochloride; 4-Amino-1,8-naphthalimide; 4-Hydroxyquinazoline; 5-AIQ hydrochloride; 5-Iodo-6-amino-1,2-benzopyrone; 6(5H)-Phenanthridinone; EB-47 dihydrochloride dihydrate; NU1025; DR2313; BSI 401; BSI 201; AZD 2281; INO 1001; GPI 15427; GPI 16539; GPI 6150; DR2313; AG14361; NU1025; CEP 6800; AG 014699; ABT-888; minocycline; tetracycline; and derivatives of these compounds.\\n9. The method of claim 7, wherein the PARP inhibitor is TIQ-A.\\n10. The method of claim 7, wherein the PARP inhibitor is a PARP-1 inhibitor","source":"patent"}'
const axios = require('axios');
const options = {
    url: "https://connect.patsnap.com/ai/ner/ddt-ner",
    method: "POST",
    headers: {
        'Content-Type': 'application/json',
        'authorization': 'Bearer {token}',
    },
    params: {
        'apikey': '',
    },
    data: {
        "lang": "en",
        "text": "Regression of Established Atherosclerotic Plaques, and Treating Sudden-Onset Asthma Attacks, using PARP Inhibitors\\n\\n\\nA method is disclosed for treating and inducing the regression of established atherosclerotic plaques. A method is disclosed for treating asthma, including treatment of an ongoing asthma attack. In both cases, treatment with PARP inhibitors, such as the PARP inhibitor TIQ-A (Thieno[2,3-c]isoquinolin-5-one), can lead to regression of existing disease and symptoms.\\n\\n\\n1. A method for relieving symptoms of a sudden-onset asthma attack in a human; said method comprising administering an effective amount of a PARP inhibitor to a human who is experiencing an acute asthma attack, wherein said PARP inhibitor is administered from 0 hours to 12 hours after the beginning of the sudden-onset asthma attack.\\n2. The method of claim 1, wherein the PARP inhibitor is administered from 0 hours to 6 hours after the beginning of the sudden-onset asthma attack.\\n3. The method of claim 1, wherein the PARP inhibitor is administered from 0 hours to 1 hours after the beginning of the sudden-onset asthma attack.\\n4. The method of claim 1, wherein the PARP inhibitor is selected from the group consisting of TIQ-A; AIQ; 3-AB; PJ-34; 1,5-Isoquinolinediol; 3-Methyl-5-AIQ hydrochloride; 4-Amino-1,8-naphthalimide; 4-Hydroxyquinazoline; 5-AIQ hydrochloride; 5-Iodo-6-amino-1,2-benzopyrone; 6(5H)-Phenanthridinone; EB-47 dihydrochloride dihydrate; NU1025; DR2313; BSI 401; BSI 201; AZD 2281; INO 1001; GPI 15427; GPI 16539; GPI 6150; DR2313; AG14361; NU1025; CEP 6800; AG 014699; ABT-888; minocycline; tetracycline; and derivatives of these compounds.\\n5. The method of claim 1, wherein the PARP inhibitor is TIQ-A.\\n6. The method of claim 1, wherein the PARP inhibitor is a PARP-1 inhibitor.\\n7. A method for inducing the regression of one or more existing atherosclerotic plaques in a human; said method comprising administering an effective amount of a PARP inhibitor over time to a human who has previously been diagnosed with one or more atherosclerotic plaques; then assaying one or more of the plaques to confirm whether one or more of the existing plaques has regressed in response to the PARP inhibitor; and then, if said assaying step indicates that one or more of the plaques has regressed, continuing further administration of the PARP inhibitor for an additional time to induce further regression of one or more of the plaques.\\n8. The method of claim 7, wherein the PARP inhibitor is selected from the group consisting of TIQ-A; AIQ; 3-AB; PJ-34; 1,5-Isoquinolinediol; 3-Methyl-5-AIQ hydrochloride; 4-Amino-1,8-naphthalimide; 4-Hydroxyquinazoline; 5-AIQ hydrochloride; 5-Iodo-6-amino-1,2-benzopyrone; 6(5H)-Phenanthridinone; EB-47 dihydrochloride dihydrate; NU1025; DR2313; BSI 401; BSI 201; AZD 2281; INO 1001; GPI 15427; GPI 16539; GPI 6150; DR2313; AG14361; NU1025; CEP 6800; AG 014699; ABT-888; minocycline; tetracycline; and derivatives of these compounds.\\n9. The method of claim 7, wherein the PARP inhibitor is TIQ-A.\\n10. The method of claim 7, wherein the PARP inhibitor is a PARP-1 inhibitor",
        "source": "patent"
    }
};
axios(options).then(res => {
    console.log(res.data)
}).catch(err => {
    console.log(err)
})
import requests
url = "https://connect.patsnap.com/ai/ner/ddt-ner"

params = {
    "apikey": ""
}

payload = {
    "lang": "en",
    "text": "Regression of Established Atherosclerotic Plaques, and Treating Sudden-Onset Asthma Attacks, using PARP Inhibitors\\n\\n\\nA method is disclosed for treating and inducing the regression of established atherosclerotic plaques. A method is disclosed for treating asthma, including treatment of an ongoing asthma attack. In both cases, treatment with PARP inhibitors, such as the PARP inhibitor TIQ-A (Thieno[2,3-c]isoquinolin-5-one), can lead to regression of existing disease and symptoms.\\n\\n\\n1. A method for relieving symptoms of a sudden-onset asthma attack in a human; said method comprising administering an effective amount of a PARP inhibitor to a human who is experiencing an acute asthma attack, wherein said PARP inhibitor is administered from 0 hours to 12 hours after the beginning of the sudden-onset asthma attack.\\n2. The method of claim 1, wherein the PARP inhibitor is administered from 0 hours to 6 hours after the beginning of the sudden-onset asthma attack.\\n3. The method of claim 1, wherein the PARP inhibitor is administered from 0 hours to 1 hours after the beginning of the sudden-onset asthma attack.\\n4. The method of claim 1, wherein the PARP inhibitor is selected from the group consisting of TIQ-A; AIQ; 3-AB; PJ-34; 1,5-Isoquinolinediol; 3-Methyl-5-AIQ hydrochloride; 4-Amino-1,8-naphthalimide; 4-Hydroxyquinazoline; 5-AIQ hydrochloride; 5-Iodo-6-amino-1,2-benzopyrone; 6(5H)-Phenanthridinone; EB-47 dihydrochloride dihydrate; NU1025; DR2313; BSI 401; BSI 201; AZD 2281; INO 1001; GPI 15427; GPI 16539; GPI 6150; DR2313; AG14361; NU1025; CEP 6800; AG 014699; ABT-888; minocycline; tetracycline; and derivatives of these compounds.\\n5. The method of claim 1, wherein the PARP inhibitor is TIQ-A.\\n6. The method of claim 1, wherein the PARP inhibitor is a PARP-1 inhibitor.\\n7. A method for inducing the regression of one or more existing atherosclerotic plaques in a human; said method comprising administering an effective amount of a PARP inhibitor over time to a human who has previously been diagnosed with one or more atherosclerotic plaques; then assaying one or more of the plaques to confirm whether one or more of the existing plaques has regressed in response to the PARP inhibitor; and then, if said assaying step indicates that one or more of the plaques has regressed, continuing further administration of the PARP inhibitor for an additional time to induce further regression of one or more of the plaques.\\n8. The method of claim 7, wherein the PARP inhibitor is selected from the group consisting of TIQ-A; AIQ; 3-AB; PJ-34; 1,5-Isoquinolinediol; 3-Methyl-5-AIQ hydrochloride; 4-Amino-1,8-naphthalimide; 4-Hydroxyquinazoline; 5-AIQ hydrochloride; 5-Iodo-6-amino-1,2-benzopyrone; 6(5H)-Phenanthridinone; EB-47 dihydrochloride dihydrate; NU1025; DR2313; BSI 401; BSI 201; AZD 2281; INO 1001; GPI 15427; GPI 16539; GPI 6150; DR2313; AG14361; NU1025; CEP 6800; AG 014699; ABT-888; minocycline; tetracycline; and derivatives of these compounds.\\n9. The method of claim 7, wherein the PARP inhibitor is TIQ-A.\\n10. The method of claim 7, wherein the PARP inhibitor is a PARP-1 inhibitor",
    "source": "patent"
}

headers = {
    "Content-Type": "application/json",
    "authorization": "Bearer {token}"
}

response = requests.request("POST", url, params=params, json=payload, headers=headers)

print(response.text)
public static void main(String[] args) {
    String host = "https://connect.patsnap.com";
    String path = "/ai/ner/ddt-ner";

    Map headers = new HashMap();
    headers.put("Content-Type", "application/json");
    headers.put("authorization", "Bearer {token}");

    Map querys = new HashMap();
    querys.put("apikey", "");
    JSONObject dataBody = (JSONObject)JSON.parse("{\"lang\":\"en\",\"text\":\"Regression of Established Atherosclerotic Plaques, and Treating Sudden-Onset Asthma Attacks, using PARP Inhibitors\\n\\n\\nA method is disclosed for treating and inducing the regression of established atherosclerotic plaques. A method is disclosed for treating asthma, including treatment of an ongoing asthma attack. In both cases, treatment with PARP inhibitors, such as the PARP inhibitor TIQ-A (Thieno[2,3-c]isoquinolin-5-one), can lead to regression of existing disease and symptoms.\\n\\n\\n1. A method for relieving symptoms of a sudden-onset asthma attack in a human; said method comprising administering an effective amount of a PARP inhibitor to a human who is experiencing an acute asthma attack, wherein said PARP inhibitor is administered from 0 hours to 12 hours after the beginning of the sudden-onset asthma attack.\\n2. The method of claim 1, wherein the PARP inhibitor is administered from 0 hours to 6 hours after the beginning of the sudden-onset asthma attack.\\n3. The method of claim 1, wherein the PARP inhibitor is administered from 0 hours to 1 hours after the beginning of the sudden-onset asthma attack.\\n4. The method of claim 1, wherein the PARP inhibitor is selected from the group consisting of TIQ-A; AIQ; 3-AB; PJ-34; 1,5-Isoquinolinediol; 3-Methyl-5-AIQ hydrochloride; 4-Amino-1,8-naphthalimide; 4-Hydroxyquinazoline; 5-AIQ hydrochloride; 5-Iodo-6-amino-1,2-benzopyrone; 6(5H)-Phenanthridinone; EB-47 dihydrochloride dihydrate; NU1025; DR2313; BSI 401; BSI 201; AZD 2281; INO 1001; GPI 15427; GPI 16539; GPI 6150; DR2313; AG14361; NU1025; CEP 6800; AG 014699; ABT-888; minocycline; tetracycline; and derivatives of these compounds.\\n5. The method of claim 1, wherein the PARP inhibitor is TIQ-A.\\n6. The method of claim 1, wherein the PARP inhibitor is a PARP-1 inhibitor.\\n7. A method for inducing the regression of one or more existing atherosclerotic plaques in a human; said method comprising administering an effective amount of a PARP inhibitor over time to a human who has previously been diagnosed with one or more atherosclerotic plaques; then assaying one or more of the plaques to confirm whether one or more of the existing plaques has regressed in response to the PARP inhibitor; and then, if said assaying step indicates that one or more of the plaques has regressed, continuing further administration of the PARP inhibitor for an additional time to induce further regression of one or more of the plaques.\\n8. The method of claim 7, wherein the PARP inhibitor is selected from the group consisting of TIQ-A; AIQ; 3-AB; PJ-34; 1,5-Isoquinolinediol; 3-Methyl-5-AIQ hydrochloride; 4-Amino-1,8-naphthalimide; 4-Hydroxyquinazoline; 5-AIQ hydrochloride; 5-Iodo-6-amino-1,2-benzopyrone; 6(5H)-Phenanthridinone; EB-47 dihydrochloride dihydrate; NU1025; DR2313; BSI 401; BSI 201; AZD 2281; INO 1001; GPI 15427; GPI 16539; GPI 6150; DR2313; AG14361; NU1025; CEP 6800; AG 014699; ABT-888; minocycline; tetracycline; and derivatives of these compounds.\\n9. The method of claim 7, wherein the PARP inhibitor is TIQ-A.\\n10. The method of claim 7, wherein the PARP inhibitor is a PARP-1 inhibitor\",\"source\":\"patent\"}");

    try {
        /**
        * Important Tips:
        * Please Download HttpUtils From
        * https://github.com/aliyun/api-gateway-demo-sign-java/blob/master/src/main/java/com/aliyun/api/gateway/demo/util/HttpUtils.java
        *
        * Please refer to the corresponding dependence:
        * https://github.com/aliyun/api-gateway-demo-sign-java/blob/master/pom.xml
        */
        HttpResponse response = HttpUtils.doPost(host, path, null, headers, querys, dataBody.toJSONString());
        System.out.println(EntityUtils.toString(response.getEntity()));
    } catch (Exception e) {
        e.printStackTrace();
    }
}
Copy

Response Parameters

CommonResponse
ParameterTypeRequiredDescriptionSample
data
arrayfalse
response data
no sample
status
booleantrue
Status
false
error_msg
stringfalse
Error Message
The request parameter format is incorrect!
error_code
integertrue
Error Code
0
NerDDTResult
ParameterTypeRequiredDescriptionSample
end
integerfalse
NER end position
53
type
stringfalse
entity type
Drug
start
integerfalse
NER start position
26
entity
stringfalse
entity name
Anti-CD19 4-1BB CAR T Cells

Response Error Details

error_codeDescription
0Success
201Created
401Unauthorized
403Forbidden
404Not Found
68300004Invalid parameter!
68300005Search api failure!
68300006Analytic basic access error!
68300007Bad request!
68300008Service error, please try again later!
68300010The file does not comply with upload specifications!
67200001API call exceeds the total limit set by the platform!
67200002Quota exceeds the limit!
67200003Access token expired or authentication error!
67200004No permission or API package quota has exceeded the limit!
67200005Insufficient balance, call failed!
67200006This client has expired and call failed!
67200007Exceeded the call limit, call failed!

Response Body

  • json
{
    "data": [
        {
            "end": 53,
            "type": "Drug",
            "start": 26,
            "entity": "Anti-CD19 4-1BB CAR T Cells"
        }
    ],
    "status": true,
    "error_code": 0
}
Copy
[AI11]News Entity Recognition(NER)